Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Antiviral Therapy

Volumn 22, Issue 4, 2017, Pages 295-305

  Trottier, Benoît ^a   Lake, Jordan E ^b   Logue, Ken ^c   Brinson, Cynthia ^d   Santiago, Lizette ^e   Brennan, Clare ^f   Koteff, Justin A ^f   Wynne, Brian ^f   Hopking, Judy ^g   Granier, Catherine ^g   Aboud, Michael ^f  

^a Clinique Medicale l'Actuel   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CascAIDS Research   (Canada)

^d Central Texas Clinical Research   (United States)

^e Hope Clinical Research   (Puerto Rico)

^f VIIV HEALTHCARE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTEGRASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OSTEOCALCIN; PROCOLLAGEN TYPE 1 N PROPEPTIDE; PROTEIN PRECURSOR; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS RNA; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DOLUTEGRAVIR; FUSED HETEROCYCLIC RINGS; LAMIVUDINE;

ADULT; AGED; ALBUMIN CREATININE RATIO; ANALYTICAL PARAMETERS; ANTIRETROVIRAL THERAPY; ARTICLE; CANADA; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC90; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOFT TISSUE DISEASE; SUBCUTANEOUS TISSUE DISORDER; SUICIDAL IDEATION; TREATMENT DURATION; UNITED STATES; VIRUS LOAD; ANTAGONISTS AND INHIBITORS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECT; DRUG SUBSTITUTION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOGENICITY; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG SUBSTITUTION; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 85028662762     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3166     Document Type: Article

References (18)

1. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research: a report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012; 60:S1–S18.
2. Abgrall S, Ingle SM, May MT, et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS 2013; 27:803–813.
3. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54:254–258.
4. Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013; 52:981–994.
5. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013; 41:353–361.
6. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55:813–821.
7. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207:740–748.
8. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 Study. Lancet 2013; 381:735–743.
9. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, Phase 2b trial. Lancet Infect Dis 2012; 12:111–118.
10. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr 2015; 70:515–519.
11. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the Phase III VIKING-3 study. J Infect Dis 2014; 210:354–362.
12. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 Infection. N Engl J Med 2013; 369:1807–1818.
13. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 Study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13:927–935.
14. Triumeq. Package insert 2015. ViiV Healthcare, Research Triangle Park, NC, USA.
15. US Department of Health and Human Services. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment, guidance for industry. (Published November 2015. Accessed 18 October 2016.) Available from http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm355128.pdf
16. Woodcock A, Bradley C. Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version. Value Health 2006; 9:320–333.
17. Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr 2014; 66:393–398.
18. Campo R, DeJesus E, Bredeek UF, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013; 56:1637–1645.